TY - JOUR
T1 - Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease
AU - Malik, Mariam E.
AU - Madelaire, Christian
AU - D'Souza, Maria
AU - Blanche, Paul
AU - Kristensen, Søren L.
AU - Kistorp, Caroline
AU - Gustafsson, Finn
AU - Køber, Lars
AU - Rørth, Rasmus
AU - McMurray, John
AU - Sattar, Naveed
AU - Gislason, Gunnar
AU - Torp-Pedersen, Christian
AU - Schou, Morten
PY - 2020
Y1 - 2020
N2 - Aims: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD. Methods and results: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen–Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02%; 95% confidence interval (CI) 3.90–4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72–3.02; P < 0.001] or ESRD (8.11%; RR 2.02; 95% CI 1.39–2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76%; RR 4.92; 95% CI 3.43–7.05; P < 0.001) the highest risk. Conclusion: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD.
AB - Aims: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD. Methods and results: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen–Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02%; 95% confidence interval (CI) 3.90–4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72–3.02; P < 0.001] or ESRD (8.11%; RR 2.02; 95% CI 1.39–2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76%; RR 4.92; 95% CI 3.43–7.05; P < 0.001) the highest risk. Conclusion: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD.
KW - End-stage renal disease
KW - Epidemiology
KW - Heart failure
KW - Type 2 diabetes
U2 - 10.1002/ejhf.1819
DO - 10.1002/ejhf.1819
M3 - Journal article
C2 - 32246806
AN - SCOPUS:85082933415
VL - 22
SP - 813
EP - 820
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 5
ER -